Markets:

Overview

News

Currencies

International

Treasuries

AbbVie (NY:ABBV)

243.51 +8.62 (+3.67%)

Streaming Delayed Price Updated: 3:19 PM EDT, Jun 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

99 100 Next >

Earnings Scheduled For April 25, 2025 ↗

April 25, 2025

Via Benzinga

US Futures Gain Amid Back-To-Back Gains On Wall Street, Nikkei Opens In The Green, Dollar Edges Higher ↗

April 24, 2025

U.S. stock futures are up Thursday night following three back-to-back days in the green during the regular session, amid growing earnings optimism and easing trade tensions.

Via Benzinga

A Glimpse of AbbVie's Earnings Potential ↗

April 24, 2025

Via Benzinga

AbbVie (ABBV) Reports Earnings Tomorrow: What To Expect

April 24, 2025

Pharmaceutical company AbbVie (NYSE:ABBV) will be reporting earnings tomorrow before market open. Here’s what investors should know.

Via StockStory

Topics Artificial Intelligence

Analyst Expectations For AbbVie's Future ↗

April 22, 2025

Via Benzinga

Is the Market Bullish or Bearish on AbbVie? ↗

April 21, 2025

Via Benzinga

Bristol Myers' Cobenfy Falls Short On Primary Endpoint In Phase 3 Schizophrenia Trial, Stock Slides ↗

April 23, 2025

Bristol Myers' Cobenfy missed its primary endpoint in the Phase 3 ARISE trial but showed symptom improvement in certain subgroups.

Via Benzinga

Salesforce, AbbVie, Intuitive Surgical And An Industrial Stock On CNBC's 'Final Trades' ↗

April 23, 2025

Via Benzinga

2 High-Yield Dividend Stocks to Buy for Passive Income ↗

April 23, 2025

Via The Motley Fool

Topics Retirement

AbbVie's Pipeline May Be A 2026 Story, But Analyst Likes The Setup Now ↗

April 22, 2025

Cantor Fitzgerald starts AbbVie with an Overweight rating and $210 target, citing strong drug growth, low risk, and no major patent concerns.

Via Benzinga

Topics Intellectual Property

Spotlight on AbbVie: Analyzing the Surge in Options Activity ↗

April 22, 2025

Via Benzinga

AbbVie Options Trading: A Deep Dive into Market Sentiment ↗

April 15, 2025

Via Benzinga

AbbVie Unusual Options Activity ↗

April 11, 2025

Via Benzinga

This StoneCo Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗

April 22, 2025

Via Benzinga

This American Water Works Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Tuesday ↗

April 22, 2025

Via Benzinga

Is AbbVie Stock a Buy? ↗

April 20, 2025

The pharmaceutical giant has been a roller coaster over the past several months.

Via The Motley Fool

Topics Government Intellectual Property World Trade

A Congress Member Sold Up To $120K In AbbVie Stock: Here's What You Need To Know ↗

April 18, 2025

Via Benzinga

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today ↗

April 18, 2025

Via Benzinga

Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction ↗

April 16, 2025

Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating...

Via Benzinga

Topics Government

Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks

April 16, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with AbbVie...

Via StockStory

Topics Artificial Intelligence

34-Year-Old Making $3,400 a Month in Dividends Shares His Top 7 Stocks — 'Be Lucky and Save Relentlessly' ↗

April 14, 2025

Via Benzinga

After The Tariff Flush, A Fresh Look At AbbVie Pharma ↗

April 14, 2025

If ABBV has truly made a bottom, we should see it clear and close over 182.

Via Talk Markets

Topics Stocks / Equities

Meta, TJX, Taiwan Semiconductor Manufacturing And A Health Care Stock: CNBC's 'Final Trades' ↗

April 14, 2025

Via Benzinga

Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight ↗

April 11, 2025

Omeros forms oncology committee to guide development of its AML therapy, which showed strong efficacy and safety in preclinical studies targeting leukemia cells.

Via Benzinga

Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies ↗

April 11, 2025

Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs.

Via Benzinga

Topics Government World Trade

S&P, Dow Jones Pharma Names Rattled — Again — On Trump's Tariffs Whiplash ↗

April 10, 2025

Here's why the 90-day tariffs delay doesn't help pharmaceutical companies.

Via Investor's Business Daily

Topics Government Stocks World Trade

3 Biopharmaceutical Stocks Bucking the Sell-Off

April 10, 2025

Three biopharma companies may appeal to investors looking for firms that have not been rocked by tariff-inspired turbulence.

Via MarketBeat

Topics World Trade

The Last Time the Stock Market Started a Year This Badly Was 2022. Is Another Crash Coming? ↗

April 10, 2025

Via The Motley Fool

Topics Economy Government World Trade

What's going on in today's session: S&P500 movers ↗

April 09, 2025

Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Wednesday.

Via Chartmill

These S&P500 stocks are gapping in today's session ↗

April 09, 2025

Stay updated with the S&P500 gap up and gap down stocks on Wednesday. Get a glimpse of the market's movement during today's session.

Via Chartmill

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.